

**IN THE CLAIMS:**

The following is a listing of the claims currently pending in the above-identified application. It recites all amendments of the claims. This listing of claims will replace all prior versions and listings of claims in the application.

1-22. (Cancelled)

23. (Currently Amended) A compound of formula (1) selected from:

6-[2-hydroxy-2-(4-chlorophenyl)ethyl]-2,4-di-N-pyrrolidinylpyrimidine,

6-[2-hydroxy-2-(3-trifluoromethoxyphenyl)ethyl]-2,4-di-N-pyrrolidinylpyrimidine and

6-[2-hydroxy-2-(2-methylphenyl)ethyl]-2,4-di-N-pyrrolidinylpyrimidine[.], or pharmaceutically acceptable salts thereof, solvate thereof, or prodrugs thereof.

24. (Cancelled)

25. (Currently Amended) A method for the therapeutic treatment of ischemic disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to Claim [1] 23.

26. (Currently Amended) A method for the therapeutic treatment of diseases selected from the group consisting of head trauma, stroke, cardiac arrest, ischemia, hypoxia, hypoglycemia and epilepsy comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to Claim [1] 23.

27. (New) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to Claim 23 and a pharmaceutical acceptable carrier, diluent, adjuvant, or excipient thereof.